ArticleBMC geriatrics2025
Effectiveness of sarcopenia screening indicators in predicting death in older patients with chronic heart failure.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study investigated the associations between multiple sarcopenia screening indicators and the risk of mortality, both overall and within 30 days of discharge, in older patients with chronic heart failure (CHF). MATERIALS AND
methodsThis retrospective study enrolled inpatients aged ≥ 60 years diagnosed with CHF in a teaching hospital in western China. The general data of the patients between January 1, 2017 and July 7, 2022 were collected from the electronic medical record system, and information on mortality was obtained through telephonic follow-up from July 31, 2022 to August 1, 2022. Cox regression analysis was used to explore the possible association between sarcopenia screening indicators, including the serum creatinine (Cr)/cystatin C (CysC)*100 and AST/ALT ratios, as well as the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), and risk of mortality, both overall and within 30 days of discharge.
resultsThis study included 482 older patients with CHF, including 270 males (56.02%) and 169 patients (35.06%) who died. After adjustment for possible confounding factors, Cox regression analysis showed that compared with patients with PLR<125.11, those with PLR ≥ 125.11 had a higher risk of death within 30 days after discharge (HR = 3.75, 95% CI:1.09-12.94) as well as overall mortality (HR=1.82, 95%CI: 1.14-2.93). However, Cr/CysC*100, AST/ALT, and NLR were not associated with either overall or 30-day mortality risk.
conclusionThe PLR was found to be associated with the risk of both overall mortality and death within 30 days of discharge in older patients with CHF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.